title: Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children.
abstract: To test the hypothesis that surfactant nebulization improves pulmonary function and reduces bronchial responsiveness to histamine, we studied 12 children with asthma. We measured before and after inhalation of 100 mg nebulized natural-derived bovine surfactant (Alveofact (registered)) and after nebulization of 0.9% NaCl the change in peak expiratory flow, vital VC, FEV1, and forced expiratory flows at 50 and 75% of the flow-volume curve. In addition, we performed a histamine inhalation challenge. We did not find any significant changes in these parameters after nebulization of surfactant. These findings indicate that the inhalation of nebulized surfactant does not alter airflow obstruction and does not alter bronchial responsiveness to histamine in asthmatic children with airflow obstruction.
authors.affiliation: Department of Pediatrics, University Hospital Groningen, the Netherlands.
authors.forename: S B
authors.initials: SB
authors.lastname: Oetomo
authors.forename: C
authors.initials: C
authors.lastname: Dorrepaal
authors.forename: H
authors.initials: H
authors.lastname: Bos
authors.forename: J
authors.initials: J
authors.lastname: Gerritsen
authors.forename: T W
authors.initials: TW
authors.lastname: van der Mark
authors.forename: G H
authors.initials: GH
authors.lastname: Koëter
authors.forename: W M
authors.initials: WM
authors.lastname: van Aalderen
mesh_terms: D000293:Adolescent; D000336:Aerosols; D000402:Airway Obstruction / Q000517:prevention & control*; D000818:Animals; D001249:Asthma / Q000517:prevention & control*; D001985:Bronchial Provocation Tests; D016085:Bronchoconstrictor Agents; D002417:Cattle; D002648:Child; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005541:Forced Expiratory Volume / Q000187:drug effects; D006632:Histamine; D006801:Humans; D008055:Lipids / Q000627:therapeutic use; D008450:Maximal Midexpiratory Flow Rate / Q000187:drug effects; D009330:Nebulizers and Vaporizers; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D010743:Phospholipids; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D017211:Treatment Failure; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D000336:Aerosols; D016085:Bronchoconstrictor Agents; D008055:Lipids; D010743:Phospholipids; D011663:Pulmonary Surfactants; C078272:SF-RI 1, bovine surfactant preparation; D006632:Histamine